Related Experiment Video
Updated: May 8, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
An experimental therapy to improve skeletal growth and prevent bone loss in a mouse model overexpressing IL-6
A Del Fattore1, A Cappariello, M Capulli
1Bambino Gesù Children's Hospital, IRCCS, Piazza Sant'Onofrio 4, 00165, Rome, Italy, andrea.delf@gmail.com.
Insights
Sequential Fc-OPG/hPTH treatment effectively improved skeletal growth and prevented bone loss in juvenile inflammatory disease models. This experimental therapy offers a promising approach for treating bone defects in children.
Area of Science:
- * Molecular Endocrinology
- * Pediatric Bone Biology
- * Inflammatory Disease Pathophysiology
Background:
- * Childhood chronic inflammatory diseases often lead to premature osteoporosis and stunted growth, significantly impacting quality of life.
- * Current treatment options for these juvenile bone defects are limited.
- * Interleukin-6 (IL-6) overexpression in mice serves as a model for studying these inflammatory bone complications.
Purpose of the Study:
- * To investigate the efficacy of a sequential treatment regimen combining Fc-osteoprotegerin (Fc-OPG) and human parathyroid hormone (hPTH) in a mouse model of IL-6-induced bone disease.
- * To evaluate the potential of this combined therapy to reverse bone loss and growth impairment.
Main Methods:
- * Growing mice overexpressing IL-6 were used as a disease model.
- * Treatment involved sequential administration of Fc-OPG (single dose) and hPTH(1-34) (daily injections) during critical developmental periods.
- * Bone resorption and formation markers, including osteoclast and osteoblast activity, were assessed.
Main Results:
- * Sequential Fc-OPG/hPTH treatment completely prevented growth defects and bone loss in IL-6 overexpressing mice.
- * The therapy normalized osteoclast and osteoblast parameters, restoring normal bone turnover.
- * Individual treatments with Fc-OPG or hPTH partially improved bone parameters, highlighting the synergy of the combined approach.
Conclusions:
- * Sequential Fc-OPG/hPTH treatment is a viable experimental therapy for improving skeletal growth and preventing bone loss in models of juvenile inflammatory diseases.
- * This study provides proof of principle for a novel therapeutic strategy targeting bone complications associated with chronic inflammation in children.
- * Further research is warranted to translate these findings into clinical applications for pediatric patients.
Unlabelled:
Premature osteoporosis and stunted growth are common complications of childhood chronic inflammatory disease. Presently, no treatment regimens are available for these defects in juvenile diseases. We identified the sequential Fc-OPG/hPTH treatment as an experimental therapy that improves the skeletal growth and prevents the bone loss in a mouse model overexpressing IL-6.
Introduction:
Premature osteoporosis and stunted growth are common complications of childhood chronic inflammatory diseases and have a significant impact on patients' quality of life. Presently, no treatment regimens are available for these defects in juvenile diseases. To test a new therapeutic approach, we used growing mice overexpressing the pro-inflammatory cytokine IL-6 (TG), which show a generalized bone loss and stunted growth.
Methods:
Since TG mice present increased bone resorption and impaired bone formation, we tested a combined therapy with the antiresorptive modified osteoprotegerin, Fc-OPG, and the anabolic PTH. We injected TG mice with Fc-OPG once at the 4th day of life and with hPTH(1-34) everyday from the 16th to the 30th day of age.
Results:
A complete prevention of growth and bone defects was observed in treated mice due to normalization of osteoclast and osteoblast parameters. Re-establishment of normal bone turnover was confirmed by RT-PCR analysis and by in vitro experiments that revealed the full rescue of osteoclast and osteoblast functions. The phenotypic recovery of TG mice was due to the sequential treatment, because TG mice treated with Fc-OPG or hPTH alone showed an increase of body weight, tibia length, and bone volume to intermediate levels between those observed in vehicle-treated WT and TG mice.
Conclusions:
Our results identified the sequential Fc-OPG/hPTH treatment as an experimental therapy that improves the skeletal growth and prevents the bone loss in IL-6 overexpressing mice, thus providing the proof of principle for a therapeutic approach to correct these defects in juvenile inflammatory diseases.
